Literature DB >> 3181183

Modification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma.

G M Blake1, V J Lewington, J S Fleming, M A Zivanovic, D M Ackery.   

Abstract

Following a case report that oral nifedipine can suppress the secretion of noradrenaline by phaeochromocytoma, we examined the effect of nifedipine on the tumour kinetics of tracer 131I-meta-iodobenzylguanidine (131I-mIBG) in five patients referred for mIBG radionuclide therapy for disseminated malignant phaeochromocytoma. In one subject a striking modification of mIBG kinetics was found that resulted in a doubling of the absorbed dose to tumour while the patient was taking nifedipine. At the same time, urinary excretion of noradrenaline was suppressed by a factor of three. The effect of nifedipine in this patient was confirmed when tracer studies were repeated nine months later. The changes in tumour kinetics were shown to be due to prolonged retention of mIBG rather than increased tumour blood flow or alteration of the curve of mIBG plasma concentration as a function of time.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3181183     DOI: 10.1007/bf00254381

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  8 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

2.  In vivo quantitation of lesion radioactivity using external counting methods.

Authors:  S R Thomas; H R Maxon; J G Kereiakes
Journal:  Med Phys       Date:  1976 Jul-Aug       Impact factor: 4.071

3.  The first pass metabolism of nifedipine in man.

Authors:  D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

Review 4.  Radioiodinated iodobenzylguanidines for diagnosis and therapy.

Authors:  A J McEwan; P Wyeth; D Ackery
Journal:  Int J Rad Appl Instrum A       Date:  1986

5.  Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine.

Authors:  C A Hoefnagel; P A Voûte; J de Kraker; H R Marcuse
Journal:  J Nucl Med       Date:  1987-03       Impact factor: 10.057

6.  Radiopharmaceutical treatment of malignant pheochromocytoma.

Authors:  J C Sisson; B Shapiro; W H Beierwaltes; J V Glowniak; M Nakajo; T J Mangner; J E Carey; D P Swanson; J E Copp; W G Satterlee
Journal:  J Nucl Med       Date:  1984-02       Impact factor: 10.057

7.  Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine.

Authors:  M C Tobes; S Jaques; D M Wieland; J C Sisson
Journal:  J Nucl Med       Date:  1985-08       Impact factor: 10.057

8.  Phaeochromocytoma and hypertrophic cardiomyopathy: apparent suppression of symptoms and noradrenaline secretion by calcium-channel blockade.

Authors:  D Serfas; D M Shoback; B H Lorell
Journal:  Lancet       Date:  1983-09-24       Impact factor: 79.321

  8 in total
  10 in total

Review 1.  Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature.

Authors:  Arnold F Jacobson; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2015-05-15       Impact factor: 5.952

Review 2.  Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry.

Authors:  A R Wafelman; C A Hoefnagel; R A Maes; J H Beijnen
Journal:  Eur J Nucl Med       Date:  1994-06

Review 3.  Drug interactions with radiopharmaceuticals.

Authors:  S Hesslewood; E Leung
Journal:  Eur J Nucl Med       Date:  1994-04

Review 4.  The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.

Authors:  K C Loh; P A Fitzgerald; K K Matthay; P P Yeo; D C Price
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

5.  Glomerular filtration rate and the kinetics of 123I-metaiodobenzylguanidine.

Authors:  G M Blake; V J Lewington; M A Zivanovic; D M Ackery
Journal:  Eur J Nucl Med       Date:  1989

6.  European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

Authors:  David Taïeb; Rodney J Hicks; Elif Hindié; Benjamin A Guillet; Anca Avram; Pietro Ghedini; Henri J Timmers; Aaron T Scott; Saeed Elojeimy; Domenico Rubello; Irène J Virgolini; Stefano Fanti; Sona Balogova; Neeta Pandit-Taskar; Karel Pacak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-29       Impact factor: 9.236

7.  131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.

Authors:  Gonca Kara Gedik; Cornelis A Hoefnagel; Evert Bais; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-11       Impact factor: 9.236

8.  EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.

Authors:  David Taïeb; Henri J Timmers; Elif Hindié; Benjamin A Guillet; Hartmut P Neumann; Martin K Walz; Giuseppe Opocher; Wouter W de Herder; Carsten C Boedeker; Ronald R de Krijger; Arturo Chiti; Adil Al-Nahhas; Karel Pacak; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

Review 9.  Radionuclide therapy revisited.

Authors:  C A Hoefnagel
Journal:  Eur J Nucl Med       Date:  1991

10.  The uptake and retention of metaiodobenzyl guanidine by the neuroblastoma cell line NB1-G.

Authors:  R J Mairs; M N Gaze; A Barrett
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.